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Over the past 20 years, clinical research has focused on the development of reperfusion
therapies for acute ischemic stroke (AIS), which include the use of systemic intravenous
thrombolytics (alteplase, desmoteplase, or tenecteplase), the augmentation of systemic
intravenous recanalization with ultrasound, the bridging of intravenous with intra-arterial
thrombolysis, the use of multi-modal approaches to reperfusion including thrombectomy
and thromboaspiration with different available retrievers. Clinical trials testing these acute
reperfusion therapies provided novel insight regarding the comparative safety and efficacy,
but also raised new questions and further uncertainty on the field. Intravenous alteplase
(tPA) remains the fastest and easiest way to initiate acute stroke reperfusion treatment, and
should continue to be the first-line treatment for patients with AIS within 4.5 h from onset.
The use of tenecteplase instead of tPA and the augmentation of systemic thrombolysis with
ultrasound are both novel therapeutical modalities that may emerge as significant options
in AIS treatment. Endovascular treatments for AIS are rapidly evolving due to technological
advances in catheter-based interventions and are currently emphasizing speed in order to
result in timely restoration of perfusion of still-salvageable, infarcted brain tissue, since
delayed recanalization of proximal intracranial occlusions has not been associated with
improved clinical outcomes. Comprehensive imaging protocols in AIS may enable better
patient selection for endovascular interventions and for testing multi-modal combinatory
strategies.
Keywords: reperfusion therapies, stroke, cerebral ischemia, sonothrombolysis, thrombolysis, intravenous, intra-
arterial
INTRODUCTION
Over the last decade, various therapeutic approaches have been
developed for treating acute ischemic stroke (AIS) patients pre-
senting with severe neurological deficits (1). As immediate and
successful restoration of blood flow in the ischemic tissue was
proved to be the paramount target in the treatment of acute
cerebral ischemia (2), ongoing clinical research focused on the
development of reperfusion therapies for AIS. Reperfusion strate-
gies that were tested in clinical trials include the use of sys-
temic intravenous tPA (3) tenecteplase (4, 5), or desmolteplase
(6, 7) the augmentation of systemic tPA-induced recanalization
using ultrasound (8, 9), the bridging of intravenous with intra-
arterial thrombolysis (10), the use of endovascular multi-modal
approaches to reperfusion including mechanical thrombectomy
or thromboaspiration using different stent retrievers (11–19)
(Tables 1 and 2).
In the present narrative review, we summarize the evolution
of systemic intravenous and endovascular reperfusion strategies
for AIS treatment, highlight the comparative safety and efficacy
of these modalities, and underscore their potentials and limita-
tions and comment on the future directions of acute reperfusion
therapies in acute cerebral ischemia.
SYSTEMIC REPERFUSION THERAPIES
INTRAVENOUS FIBRINOGEN-DEPLETING AGENTS
Fibrinogen-depleting agents may help the restoration of blood
flow after an ischemic stroke by reducing the fibrinogen in blood
plasma (20). A continuous 72-h intravenous infusion of the defib-
rinogenerating agent Ancrod beginning within 3 h of stroke onset,
followed by infusions lasting approximately 1 h at 96 and 120 h
was found to have a favorable benefit–risk profile for patients with
AIS in The Stroke Treatment with Ancrod Trial (STAT). The pro-
portion of severely disabled patients was less in the ancrod group
than in the placebo group, and this observation was independent
from age, stroke severity, sex, prestroke disability, and time to treat-
ment. Both mortality and symptomatic intracerebral hemorrhage
rates were not found to be different between treatment groups.
However, patients randomized to ancrod were found to have more
frequently asymptomatic intracranial hemorrhages compared to
placebo (21). In both the subsequent European STAT and the
Ancrod Stroke Program, functional 3-month outcome was not
found to be significantly different between patients randomized
to ancrod or placebo within 6 h of stroke onset (22).
In a meta-analysis of randomized trials, the use of fibrinogen-
depleting agents within 14 days of stroke onset was marginally
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Table 1 | Characteristics of acute reperfusion trials in ischemic stroke.
Study Type Centers Phase Subgroup N Agea Females (%) Baseline
NIHSSb
OTT (h)
NINDS (3) RCT 9 III IV-tPA 168 69±12.0 43 14 1.5
Placebo 165 66±13.0 42 15 1.5
TAAIS (5) RCT 4 IIb IV-TNK (0.1 mg/kg) 25 72±6.9 48 15±2 3.1
IV-TNK (0.25 mg/kg) 25 68±9.4 48 15±2 3.0
IV-tPA 25 70±8.4 52 14±2 2.7
DIAS (6) RCT 44 II IV-desmoteplase 75 68 45 12 5.4
Placebo/SOC 22 68 48 12 5.4
DIAS II (7) RCT 52 III IV-desmoteplase
(90 mcg/kg)
57 67.9±13.4 53 11±6 6.5
IV-desmoteplase
(125 mcg/kg)
66 70±12.3 56 10±5 6.7
CLOTBUST (8) RCT 3 II IV-tPA+TCD 63 67±11.9 35 15 2.5
IV-tPA 63 70±13.1 52 15±6 2.2
TUCSON (9) RCT 14 II IV-tPA+TCD+MB (1.4 ml) 12 63±15.0 54 9±6 2.6
IV-tPA+TCD+MB (2.8 ml) 11 68±15.0 17 16 (9–21) 2.2
IV-tPA 12 65±14.0 33 12 (7–14) 2.1
IMS III (10) RCT 71 III IA-tPA+MT 434 69 (23–89) 50 17 4.2
IV-tPA 222 68 (23–84) 45 16 2.0
PROACT II (11) RCT 54 II IA-ProUK 121 64±14.0 42 17 4.7
Placebo 59 64±14.0 39 17 5.1
MERCI (12) SA 25 II MT-MERCI 141 67±15.5 46 20±7 4.3
Multi-MERCI (13) SA 15 II MT-MERCI 164 68.1±16.0 57 19 4.3
PENUMBRA PST (14) SA 24 II MT-penumbra 125 63.5±13.5 49 18±5 4.3
PENUMBRA POST (15) SA 7 IV MT-penumbra 157 65±15.0 46 16±6 4.5
SWIFT (16) RCT 18 II MT-solitaire 58 67.1±12.0 52 17±5 4.9
MT-MERCI 55 67.1±11.0 49 18±5 5.3
TREVO 2 (17) RCT 7 III MT-Trevo 88 67.4±13.9 55 18±5 4.6
MT-MERCI 90 67±14.7 60 18±5 4.5
MR-Rescue (18) RCT 22 IIb MT (+IV-tPA)(+IA-tPA)-
penumbral
34 66.4±13.2 43 16 (11–18) 6.0
MT (+ IV-tPA)(+ IA-tPA)-non-
penumbral
30 61.6±12.0 57 21 (17–22) 6.0
IV-tPA/SOC-penumbral 34 65.8±16.9 56 16 (11–18) 5.8
IV-tPA/SOC-non-penumbral 20 69.4±15.9 40 21 (17–23) 5.7
Synthesis expansion (19) RCT 24 III IA-tPA+MT 181 66±11.9 41 13 (9–17) 3.8
IV-tPA 181 67±11.9 43 13 (9–18) 2.8
N, number of patients; RCT, randomized clinical trial; SA, single-arm study; OTT, onset-to-treatment time; NIHSS, National Institute of Health Stroke Scale; h, hours;
TCD, transcranial Doppler; IV, intravenous; tPA, alteplase;TNK, tenecteplase; UK, urokinase; IA, intra-arterial; MT, mechanical thrombectomy; MB, microbubbles; SOC,
standard of care. The values that are presented solely without corresponding SDs or IQRs, is because these data were not provided from the original publications.
anumbers in parentheses indicate the corresponding range; bnumbers in parentheses indicate the corresponding interquartile range (IQR).
related with a decreased risk of unfavorable outcome and stroke
recurrence at follow-up, but with a double risk of symptomatic
intracranial hemorrhage (23).
THROMBOLYSIS WITH STREPTOKINASE
Both the Multicentre Acute Stroke Trial-Italy (MAST-I) and Mul-
ticenter Acute Stroke Trial-Europe (MAST-E) resulted that strep-
tokinase cannot be recommended in AIS, as intravenous infusion
of 1.5 MU streptokinase (1.5 MU for 1 h) within 6 h of stroke
onset was associated with a significantly higher 10-day mortality
compared to 300 mg/day buffered aspirin (24, 25). However, data
from the Australian Streptokinase (ASK) Trial Study Group sug-
gested that 1.5 MU intravenous streptokinase for 1 h within 3 h of
stroke was safer and associated with significantly better outcomes
than later treatment, as poor outcomes were confined to patients
receiving therapy more than 3 h after stroke onset (26).
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Table 2 | Safety and efficacy outcomes of acute reperfusion trials in ischemic stroke.
Study Subgroup 90 d mRS=
0–1 (%)
90 d mRS=
0–2 (%)
Mortality
(%)
sICH
(%)
Successful
recanalization
NINDS (3) IV-tPA 39 – 17 6.4 –
Placebo 26 – 21 0.6 –
TAAIS (5) IV-TNK (0.1 mg/kg) 54 64 8 4 36
IV-TNK (0.25 mg/kg) 54 64 8 0 35
IV-tPA 40 44 12 4 80
DIAS (6) IV-desmoteplase – 39 4 12 49.3
Placebo/SOC – 22 3 0 19.2
DIAS II (7) IV-desmoteplase (90 mcg/kg) – 54 5 3.5 –
IV-desmoteplase (125 mcg/kg) – 48 21 4.5 –
– 57 6 0 –
CLOTBUST (8) IV-tPA+TCD 42 51 15 4.8 49
IV-tPA 29 37 18 4.8 30
TUCSON (9) IV-tPA+TCD+MB (1.4 ml) 75 83 9 0 67
IV-tPA+TCD+MB (2.8 ml) 50 60 30 27 46
IV-tPA 36 55 0 0 33
IMS III (10) IA-tPA+MT 29 43 19.1 6.2 ICA:81; M1-MCA: 86;
M2-MCA:88; BA: 100
IV-tPA 27 40 21.6 5.9 ICA: 35; M1-MCA: 68;
M2-MCA: 77
PROACT II (11) IA-ProUK 26 40 25 10 –
Placebo 17 25 27 4 –
MERCI (12) MT-MERCI – 28 8 44 48
Multi-MERCI (13) MT-MERCI – 36 34 9.8 69.5
PENUMBRA PST (14) MT-penumbra – 25 32.8 11.2 81.6
PENUMBRA POST (15) MT-penumbra – 41 20 6 87
SWIFT (16) MT-solitaire 26 28 17 2 61
MT-MERCI 18 27 38 11 24
TREVO 2 (17) MT-Trevo 27 40 34 – 86
MT-MERCI 15 22 24 – 60
MR-Rescue (18) MT (+ IV-tPA)(+ IA-tPA)-penumbral 9 14 16 9 77
MT (+ IV-tPA)(+ IA-tPA)-non-penumbral 6 10 23 0 62
IV-tPA/SOC-penumbral 15 23 9 6 –
IV-tPA/SOC-non-penumbral 6 10 22 0 –
Synthesis expansion (19) IA-tPA+MT 30 42 14 6 –
IV-tPA 35 31 10 6 –
mRS, modified Ranking Scale; sICH, symptomatic intracerebral hemorrhage; TCD, transcranial Doppler; IV, intravenous; tPA, alteplase; TNK, tenecteplase; UK,
urokinase; IA, intra-arterial; MT, mechanical thrombectomy; MB, microbubbles; SOC, standard of care.
THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR
Intravenous thrombolysis with tissue plasminogen activator (tPA)
remains the only evidence-based treatment for AIS and is the
fastest and easiest way to initiate acute reperfusion treatment with
a 24/7 availability even in primary stroke centers (3). Selection
for this treatment remains simple and expeditious requiring only
the presence of a disabling neurological deficit, bleeding exclusion
(with non-contrast head CT scan), and determination of time
from symptom onset (27, 28). However, only a minority of stroke
patients arrive in time to be eligible for this treatment (29).
To date, patients with wake-up ischemic stroke are excluded
from intravenous thrombolysis per se in daily clinical practice,
even if they meet all other criteria for treatment. However, emerg-
ing data suggest that intravenous thrombolysis in carefully selected
wake-up stroke patients, showing no or early ischemic changes on
brain imaging, might be safe and effective comparable to those
patients with known time of symptom onset (30, 31). Apart
from intravenous thrombolysis trials, wake-up stroke patients
could also be excellent candidates for future endovascular stroke
trials.
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The dose of tPA is calculated using patient’s weight and not
based on thrombus weight and the success of the treatment is inde-
pendent from the presence of residual flow that exposes shallow
layers of thrombus to circulating tPA (32). In most cases, intra-
venous tPA induces partial recanalization, since stroke patients
often have large thrombus burden (33). Thus, the presence of a
proximal arterial occlusion does not necessarily lead to tPA fail-
ure, since some degree of recanalization can occur even with large
thrombi (33, 34).
Time matters in the clinical outcome of AIS not only as the
time from symptom onset to the initiation of treatment but also
in the speed of thrombolysis once the tPA infusion is initiated
(35–37). With the latest advances in extending the timeframe for
IVT (to 4.5 h from symptom onset) (27, 28) and improvement
in imaging modalities (to select appropriate candidates for acute
reperfusion therapies), it becomes apparent that the efficacy of sys-
temic thrombolysis is time-dependent and as onset-to-treatment
time increases the percentage of AIS patients with potentially sal-
vageable infarcted brain tissue decreases (38–40). The finding that
shorter time to treatment translates into faster recanalization and
better clinical recovery has also been suggested by a meta-analysis
of studies that evaluated recanalization for stroke treatment (41).
This hypothesis is currently investigated by prospectively acquired
data from the ongoing CLOTBUST-PRO (PROspective multi-
national CLOTBUST collaboration on reperfusion therapies for
AIS) observational study (42).
INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE
The high rates of unsuccessful reperfusion observed with tPA
in patients with large thrombus burden (clots located at termi-
nal internal carotid artery, tandem extracranial internal carotid
artery/middle cerebral artery occlusions) triggered the search for
other thrombolytic agents in AIS (43, 44). Tenecteplase (TNK) is a
genetically engineered variant of tPA that has a longer half-life and
is more fibrin specific than tPA. These properties make TNK a very
advantageous thrombolytic to induce faster and more complete
clot lysis, with less bleeding complications and early re-occlusions
(45). An additional benefit is that TNK can be administered by a
single intravenous bolus without the need of infusion (46). Even
though TNK has already been approved for the treatment of acute
myocardial infarction, the use of TNK instead of tPA in the treat-
ment of AIS outside of the setting of a clinical trial still remains
unapproved (46, 47).
Only two randomized clinical trials (phase IIB) comparing tPA
to TNK in acute stroke patients have been published to date. In
the study conducted by the Tenecteplase in Stroke Investigators
different tenecteplase doses (0.1, 0.25, and 0.4 mg/kg) were com-
pared with standard 0.9 mg/kg rt-PA dose in patients with acute
stroke within 3 h of onset to establish the optimal TNK dose for the
subsequent phase III trial. The trial was prematurely terminated
for slow enrollment, as between 2006 and 2008 only 112 patients
had been randomized at 8 clinical centers. No statistically signif-
icant differences were found in the 3-month outcome between
the TNK and tPA groups, while symptomatic intracranial hemor-
rhage rates were found to be highest in the 0.4 mg/kg tenecteplase
group and lowest in the 0.1 mg/kg tenecteplase group (4). In the
Tenecteplase versus Alteplase for Acute Ischemic Stroke (TAAIS)
trial 75 patients, who arrived <6 h after the onset of ischemic stroke
with a perfusion lesion at least 20% greater than the infarct core on
CT perfusion imaging at baseline and an associated vessel occlu-
sion on CT angiography, were randomly assigned to receive either
tPA (0.9 mg/kg) or TNK (0.1 mg/kg or 0.25 mg/kg). Both TNK
groups were found to have greater reperfusion rates and better clin-
ical improvement at 24 h than the tPA group, while no significant
differences in intracranial bleeding or other serious adverse events
were noted between the groups. Additionally, the higher dose of
TNK (0.25 mg/kg) was found to be superior to both the lower TNK
dose of 0.1 mg/kg and to tPA for all efficacy outcomes, including
the 3-month functional outcome (5). In a comprehensive benefit–
risk analysis, TAAIS was found to have the higher benefit-to-risk
ratio among all acute reperfusion therapies for AIS, followed by
sonothrombolysis trials (48). However, it should be noted that the
inclusion criteria of TAAIS in imaging greatly favored the selection
of patients most likely to benefit from thrombolytic therapy.
INTRAVENOUS THROMBOLYSIS WITH DESMOTEPLASE
Because of its high fibrin specificity, non-activation by β-
amyloid, long ER terminal half-life and absence of neurotoxicity,
desmoteplase is an attractive alternative to alteplase for systemic
thrombolytic treatment of AIS (49, 50).
The desmoteplase in acute stroke (DIAS) trial was a safety
and dose-finding phase IIb trial in AIS patients with a perfusion-
diffusion mismatch on MRI within 3–9 h of symptom onset (6).
Initially, patients were randomized to intravenous desmoteplase
25, 37.5, or 50 mg versus placebo. However, the rate of sympto-
matic intracranial hemorrhage was high in the desmoteplase arm
and the study team decided to reduce the doses on the basis of body
weight (62.5, 90, and 125µg/kg). In turn, it was concluded that
clinical improvement was associated with early reperfusion. Over-
all, 54.3% patients treated in 3–6 h and 40% in 6–9 h time window
showed reperfusion that was significantly correlated with favorable
clinical outcome. Subsequently, a randomized, placebo-controlled,
phase III trial (DIAS-2) enrolled AIS patients presenting within 3–
9 h of onset with tissue at risk (at least 20% ischemic-penumbra
brain tissue evaluated using MRI or CT mismatch) (7). DIAS II
investigated the efficacy and safety of two doses of desmoteplase
(90 and 125µg/kg) that were administered as an i.v. bolus. The
median baseline NIHSS score was nine points and only 30% of
the recruited patients demonstrated a visible arterial occlusion at
presentation. Hence, the median core lesion and mismatch vol-
umes were small (10.6 cm3 and 52.5, respectively). There was no
significant difference in the three groups according to the improve-
ment on the NIHSS score. Mortality was 6.3% in the placebo
group, 5.3% in the 90µg/kg group, and 21.2% in the 125µg/kg
group. SICH was noted in 0, 3.5, and 4.5% of patients in the
three treatment arms, respectively. The neutral results of DIAS-
2 trial may be attributed to the low baseline NIHSS-scores, the
low rates of proximal intracranial occlusions and small absolute
mismatch volumes. However, it should be noted that when the
DIAS-2 data were analyzed with a more conservative definition
of mismatch (PWI-DWI volume >75 mL), beneficial effects of
desmoteplase were apparent in comparison to placebo (7). The
safety and efficacy of intravenous desmoteplase in AIS patients is
currently investigated in two ongoing parallel trials (DIAS-3 and
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DIAS-4),enrolling patients within a 9 h window and using updated
imaging criteria for selection of patients with target mismatch.
SONOTHROMBOLYSIS
Since intravenous tPA induces mostly partial recanalization of
large thrombi and delivery of tPA to the binding sites in the
thrombus relies on often diminished residual blood flow, early
augmentation of fibrinolysis to improve arterial recanalization
is desirable (32, 34). Ultrasound-induced mechanical agitation
of thrombus-residual flow interface can expose shallow layers of
thrombus to circulating tPA and facilitate streaming of plasma
through thrombus, thus bringing more tPA to binding cites (51–
54). Experimental in vitro and in vivo data suggested that pressure
waves from ultrasound can travel through tissues and deliver
this mechanical momentum to stagnant flow areas and thrombus
interfaces (51, 52).
Sonothrombolysis is the ultrasound targeting of an arterial
occlusive clot in order to accelerate the thrombolytic effect of
systemic tPA. Mechanical pressure waves, produced by 2 MHz
frequency ultrasound energy, can improve the delivery and pen-
etration of the thrombolytic drug inside the clot (55, 56). The
first properly powered multicenter clinical trial that confirmed
existence of ultrasound-enhanced thrombolysis in human sub-
jects was the Combined Lysis of Thrombus in Brain ischemia
using transcranial Ultrasound and Systemic TPA (CLOTBUST)
trial. In this trial, patients with acute middle cerebral artery occlu-
sions that were randomized to the combination of intravenous
thrombolysis with 2-h continuous transcranial Doppler monitor-
ing were found to achieve higher rates of recanalization within
2 h of treatment (without having higher rates of symptomatic
intracerebral hemorrhage) when compared to patients treated
only with intravenous tPA (8). A meta-analysis of six randomized
and three non-randomized clinical studies of sonothrombolysis
indicated that sonothrombolysis with high-frequency ultrasound
almost triples the likelihood of complete recanalization and dou-
bles the odds of favorable functional outcome, at no increase in
the risk of symptomatic intracerebral hemorrhage, in comparison
to standard intravenous thrombolysis (57). Similarly, two other
independent meta-analyses have also confirmed that sonothrom-
bolysis appears to reduce death or dependency at 3 months and
to increase recanalization, without further augmenting the risk of
symptomatic intracranial hemorrhage (58, 59).
Enhancement of tPA-induced recanalization can also be accom-
plished using microsphere-potentiated ultrasound-enhanced
thrombolysis combining high-frequency ultrasound with gaseous
microspheres (60–62). These intravenously injected microspheres
are able to cross the lung barrier due to their size and stability
and undergo expansion in size followed by transient oscillation or
complete break up, when intercepted intracranially by an ultra-
sound beam aimed at thrombus-residual flow interface (63–65).
With this mechanism, energy is transmitted to areas with stag-
nant flow and penetration of tPA into the thrombus is further
promoted (66, 67).
Molina et al. pioneered the use of gaseous microspheres in
combination with CLOTBUST monitoring methods and reported
safety and recanalization rates of microsphere-potentiated
sonothrombolysis in a pilot phase IIb randomized-controlled trial
(9). The Transcranial Ultrasound in Clinical SONothromboly-
sis trial (TUCSON) showed that a 1.4 mL dose of perflutren-
lipid microspheres do not augment further the risk of symp-
tomatic intracerebral hemorrhage, and thus can be safely co-
administered during tPA infusion (9, 68). The combination of
perflutren-lipid microspheres, TCD and tPA was associated with
50–67% recanalizations rates of proximal intracranial arterial
occlusions (9, 68).
The main limitation of current sonothrombolysis technol-
ogy (applied with or without microspheres) remains operator-
dependency. Skilled sonographers able to perform transcranial
Doppler or duplex are largely unavailable to the emergency depart-
ments outside a few centers worldwide (69–71). An operator-
independent 2-MHz transcranial Doppler device, developed to
provide therapeutic ultrasound regardless of sonography skills,
is currently being tested in a pivotal, multicenter, phase III
randomized-controlled trial, given the preliminary promising
results in small phase IIa/IIb safety studies (72, 73).
ENDOVASCULAR REPERFUSION THERAPIES
INTRA-ARTERIAL THROMBOLYSIS
The majority of AIS patients arrive beyond the recommended
time window for the administration of intravenous thromboly-
sis. Moreover, a substantial number of patients with large clot
burden (terminal internal carotid artery occlusions, tandem inter-
nal carotid artery/middle cerebral artery occlusions) that undergo
intravenous thrombolysis will experience no recanalization or
develop reocclusion (74, 75). Because persistence of a proximal
arterial occlusion has long been recognized as a poor prognostic
sign (2), the aforementioned considerations prompted continuing
development of catheter-based interventions in order to increase
reperfusion rates in AIS patients.
Catheters suitable for navigation into brain vasculature opened
the possibility of intra-arterial revascularization with a drug top-
ically delivered to intracranial thrombus. The Prolyse in Acute
Cerebral Thromboembolism (PROACT) trial was the first con-
trolled clinical trial that extended the timeframe up to 6 h from
symptom onset in patients with proximal middle cerebral artery
occlusions (76). This trial showed that intra-arterial pro-urokinase
administration was associated with an absolute increase of 15%
in good clinical outcomes at 3-month assessment compared to
placebo, but also reported a 10% incidence of intracranial hem-
orrhagic complications with interventions. PROACT investigators
also reported an overall recanalization rate of 66% at the comple-
tion of intra-arterial treatment (11). In a meta-analysis of random-
ized clinical trials, intra-arterial thrombolysis with either uroki-
nase or recombinant pro-urokinase administered up to 6 h after
ischemic stroke was found to increase significantly the proportion
of 3-month favorable outcome, but with a significant increase in
symptomatic intracranial hemorrhage within 24 h of treatment
(77). Despite these highly encouraging results, the US Food and
Drug Administration (FDA) did not approve pro-urokinase as an
alternative treatment for stroke and required further efficacy trials.
COMBINED ENDOVASCULAR THERAPIES
In parallel with the primary intra-arterial approach develop-
ment, the group of Interventional Management of Stroke (IMS)
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investigators started to explore “bridging” therapy, with the initi-
ation of treatment with intravenous tPA followed by intra-arterial
tPA infusion if occlusion persisted beyond the duration of sys-
temic treatment (78, 79). The phase III IMS trial compared
standard intravenous dose of tPA (0.9 mg/kg) over 1 h infusion
to 0.6 mg/kg intravenous tPA over 30 min infusion followed by
intra-arterial administration of tPA directly to the intracranial
thrombus (80). In April 2012, after 656 subjects were randomized,
the study was terminated by the National Institute of Neurolog-
ical Disorders and Stroke (NINDS) due to conditional power
criteria (81). Up to this point, the trial showed similar safety
outcomes and no significant difference in functional indepen-
dence between endovascular therapy after intravenous tPA and
intravenous tPA alone (10). However, significant differences were
identified between treatment arms for 24-h recanalization in prox-
imal occlusions, as carotid T- or L-type and tandem ICA and M1
occlusions showed greater recanalization rates and a trend toward
better outcome with endovascular treatment (82). Interestingly,
in a prespecified analysis of IMS III trial, Khatri et al. concluded
that every 30-min delay in angiographic reperfusion reduced the
relative likelihood of a favorable functional outcome at 3 months
by 15% in unadjusted analysis and 12% in adjusted analysis (83).
The observations of the IMS investigators (83) in combination
with the findings of pooled analyses of intravenous thrombol-
ysis randomized-controlled trials (37) introduce the hypothesis
that the time-dependency of the clinical efficacy of acute reper-
fusion therapies (both systemic and endovascular) in AIS may be
attributed to the time-dependency of recanalization of proximal
intracranial occlusions independent of the selected therapeutic
strategy (84).
In the randomized SYNTHESIS Expansion trial, 362 patients
with AIS within 4.5 h after onset were randomly assigned to either
intravenous tPA or endovascular therapy (intra-arterial throm-
bolysis with tPA, mechanical clot disruption or retrieval, or a
combination of these approaches). No significant differences were
found in both safety (rates of intracranial hemorrhage and death)
and long-term outcomes between the two treatment arms. How-
ever, the median time from stroke onset to the start of treatment
was significantly higher (p< 0.001) for the endovascular thera-
pies (3.75 h) compared to intravenous t-PA (2.75 h). Of the 181
patients in the endovascular treatment arm, intra-arterial throm-
bolysis with a median dose of 40 mg tPA was administered in 109
patients, a device (SOLITAIRE, PENUMBRA, TREVO, or MERCI)
was added in 56 patients, while 15 patients did not receive finally
any treatment (19).
MECHANICAL THROMBECTOMY AND ASPIRATION
Currently, the use of intra-arterial revascularization is performed
by skilled operators in centers with stroke-trained interventional-
ists (interventional neuro-radiologists, endovascular neurologists,
or neurosurgeons), and thus procedural success is highly depen-
dent on interventionalists’ skills and on the device that is used.
Mechanical thrombectomy emerged in stroke with the develop-
ment of a device called the MERCI retriever. The device deploys
a screw-like wire, which engages the thrombus and tracks it
toward proximal vessels with larger diameter, and finally aspirates
the retrieved parts of a thrombus. The initial studies (MERCI
and Multi-MERCI) showed recanalization rates of 46–57% and
symptomatic intracranial hemorrhage rates of 7.8–9.8% (12, 13).
In the cases of Multi-MERCI clinical study, when an adjunc-
tive therapy, such as intra-arterial injection of a lytic drug, was
used, recanalization rate increased to 69.5% (13). Even though
in both MERCI and Multi-MERCI studies concurrent controls
were lacking and the recanalization rates that they reported were
less of that in PROACT trial, FDA Medical Devices panel granted
approval for clinical use of MERCI retriever in stroke patients
(85). This decision was heavily criticized by many researchers, as
the spreading use of this device in routine clinical practice fur-
ther hindered the ability to test new stroke treatments with proper
controls (85).
Another device that received FDA approval after being tested
in phase I–II clinical studies without concurrent controls is the
PENUMBRA device, a device which aims to aspirate the throm-
bus from within the vessel (86). The Penumbra Pivotal Stroke
Trial enrolled 125 stroke patients presented within 8 h of symp-
tom onset, who had NIHSS ≥8 and an angiographic occlusion
of a treatable large intracranial vessel. 81.6% of the treated ves-
sels were successfully revascularized, while procedural events were
reported in 16 patients (12.8%) (14). The post-market experi-
ence of the PENUMBRA system, consisting of a retrospective
case review of 157 consecutive patients treated at 7 international
centers, reported revascularization rate, and safety profile of the
device comparable to those reported in the Pivotal trial, and a
higher proportion of patients who had good functional outcome
at 90 days assessment (15). Nevertheless, a post hoc analysis com-
paring the findings of PENUMBRA pivotal trial to the control
arm (standard intravenous thrombolysis) of two sonothrombol-
ysis trials (8, 9) reported that despite lower revascularization
rates, patients treated with systemic thrombolysis achieved bet-
ter functional outcomes likely due to earlier treatment initiation
(87). These data indicate that it is unrealistic to expect primary
intra-arterial revascularization to be any better than systemic plas-
minogen activator within the 3-h time window. Improvements in
the speed of delivery and performance of intra-arterial reperfusion
are needed.
The MERCI retriever was compared in two randomized trials
with another 2 stent retrievers: the Solitaire Flow Restoration (FR)
device, in the SOLITAIRE With the Intention For Thrombectomy
(SWIFT) trial and the TREVO, in the Thrombectomy Revascular-
ization of Large Vessel Occlusions in AIS (TREVO 2) trial. In the
SWIFT trial, 113 AIS patients with moderate to severe neurological
deficits and within 8 h of stroke symptom onset were random-
ized to receive thrombectomy treatment with either SOLITAIRE
or MERCI. The SOLITAIRE FR was found to have substantially
better angiographic, safety and clinical outcomes than the MERCI
Retrieval System. An almost twofold magnitude of difference, in
favor of the SOLITAIRE FR, was observed in good neurological
outcome at 3 months. Additionally, mortality rates were found to
be lower in the Solitaire group than in the MERCI group (17 and
38%, respectively) (16). Data from a non-randomized study proto-
col found that stent based thrombectomy with Solitaire AB device
was associated with more favorable functional outcome in patients
with proximal middle cerebral artery occlusion, when compared
to intravenous tPA (88).
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TREVO 2 was an open-label randomized-controlled trial that
recruited adult stroke patients within 8 h of symptom onset and
with angiographically confirmed large vessel occlusion. Patients
were assigned to stratified randomization (by age and NIHSS
score) to either thrombectomy with TREVO or MERCI devices.
The TREVO retriever was found to be superior to the MERCI
retriever regarding the efficacy, but the incidence of the procedure-
related adverse events did not differ significantly between groups
(15% of the patients in the Trevo group and 23% of the patients
in the Merci group) (17).
In a systematic review of available studies, mechanical
thrombectomy in AIS with a Solitaire stent was found to be
both effective and safe, with high recanalization rates (66.7–
100%) and low procedural complications (3.4%) (89). On the
basis of the aforementioned results, the FDA granted the approval
of both SOLITAIRE FR and TREVO stent-retriever devices for
the treatment of AIS due to large vessel occlusion. In view
of the higher efficacy (in terms of recanalization) and safety
(in terms of periprocedural complications), the current AHA
guidelines underscore that stent retrievers such as SOLITAIRE
FR and TREVO are generally preferred to coil retrievers such
as MERCI, when mechanical thrombectomy is pursued (Class
I; Level of Evidence A), while the relative effectiveness of the
PENUMBRA System versus stent retrievers is not yet character-
ized (27).
The MR RESCUE trial tested the hypothesis that a favorable
penumbral pattern (substantial salvageable tissue and small infarct
core) on CT or MRI scan can identify stroke patients that are
more likely to benefit from acute endovascular treatment. Patients
with confirmed large vessel occlusion were randomized to receive
either endovascular treatment (with MERCI Retriever or PENUM-
BRA System) or standard medical treatment within 8 h of anterior
ischemic stroke symptom onset, and thus four subgroups based
on perfusion results (penumbral versus non-penumbral) and type
of treatment (standard medical versus endovascular) with 20–34
patients in each group were finally generated. According to the
study outcomes, embolectomy was not found to be superior to
standard care and the presence of a favorable penumbral pattern
on neuroimaging could not identify patients who could benefit
from endovascular therapy for AIS (18).
The latest three trials of endovascular treatment of acute stroke
confirmed a strong association between the degree of success-
ful revascularization and improved clinical outcomes and the
importance of achieving rapid reperfusion. Moreover, they uncov-
ered that intravenous and intra-arterial reperfusion therapies have
similar safety profiles, including intracranial hemorrhage rates,
and thus endovascular treatments were not associated with a
greater benefit in acute stroke management compared to systemic
thrombolysis (90).
However, both intra-arterial thrombolysis and thrombectomy
may play a crucial role in providing treatment options for selected
patients with persistent after intravenous thrombolysis large vessel
occlusions (91). Current AHA/ASA guidelines suggest that intra-
arterial fibrinolysis is beneficial for treatment of carefully selected
patients with major MCA occlusion of <6 h duration who are
not otherwise candidates for intravenous rt-PA (Class I; Level of
Evidence B) and that rescue revascularization (with intra-arterial
fibrinolysis or mechanical thrombectomy) may be reasonable in
patients with large-artery occlusion who have not responded to
intravenous fibrinolysis (27).
In a recent cohort study of 536 consecutive acute stroke patients
treated with endovascular therapy, high revascularization rates
(73.9%) with low rates of symptomatic intracerebral hemorrhage
(5.6%) were noted. Age, stroke severity, hypertension, atrial fibril-
lation, and onset-to-treatment time were found to be independent
predictors of functional outcome after endovascular treatment
(92). Careful patient selection is mandatory for patients over
80 years of age, since the chances of gaining functional indepen-
dence after endovascular recanalization, despite good recanaliza-
tion rates and reasonable rates of hemorrhage, seem to be limited
(93). In a recent meta-analysis of available literature data, stenting
and mechanical thrombectomy were found to be associated with
higher recanalization rates and improved functional outcomes
compared with IA thrombolysis in AIS patients with extracra-
nial and/or intracranial internal carotid artery occlusion (94).
Finally, with the introduction of modern stent retrievers in the last
decade, mechanical thrombectomy with modern stent retrievers
has become a safe, rapid,and effective procedure with high recanal-
ization rates and low risk of procedure-related complications in
patients with basilar artery obstruction, a severe neurological and
life-threatening condition (95, 96).
CONCLUSION
Intravenous alteplase remains the fastest and easiest way to ini-
tiate acute stroke reperfusion treatment, and should continue to
be the first-line treatment for patients with AIS within 4.5 h from
onset. The use of tenecteplase instead of tPA and the augmen-
tation of systemic thrombolysis with ultrasound are both novel
therapeutical modalities that may emerge as significant options
in AIS treatment. Endovascular treatments for AIS are rapidly
evolving due to technological advances in catheter-based inter-
ventions and are currently emphasizing speed in order to result
in timely restoration of perfusion of still-salvageable, infarcted
brain tissue, since delayed recanalization of proximal intracra-
nial occlusions has not been associated with improved clin-
ical outcomes. The two stent retrievers (SOLITAIRE FR and
TREVO) that have recently been approved by FDA for the treat-
ment of AIS due to large vessel occlusion achieve faster and
higher recanalization rates resulting in better three-month clin-
ical outcomes in comparison to the older generation thrombec-
tomy (MERCI) or thromboaspiration (PENUMBRA) devices.
The safety and efficacy of stent retrievers in comparison to
standard AIS treatment (intravenous thrombolysis within 4.5 h
from symptom onset; antiplatelet therapy >4.5 h from symp-
tom onset) remains to be proved in ongoing phase III ran-
domized controlled trials [SWIFT PRIME, EXTEND-IA, THER-
APY, BASICS, REVASCAT (97)]. Comprehensive imaging pro-
tocols in AIS may enable better patient selection for endovas-
cular interventions and for testing multi-modal combinatory
strategies.
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